Savoia Carmine, Sada Lidia, Volpe Massimo
Clinical and Molecular Medicine Department, Cardiology Unit, Faculty of Medicine and Psychology, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy,
Curr Hypertens Rep. 2015 Jun;17(6):553. doi: 10.1007/s11906-015-0553-1.
Hypertension is one of the major risk factors for atrial fibrillation which in turn is the most prevalent concomitant condition in hypertensive patients. While both these pathological conditions are independent risk factors for stroke, the association of hypertension and atrial fibrillation increases the incidence of disabling strokes. Moreover, documented or silent atrial fibrillation doubles the rate of cardiovascular death. Lowering blood pressure is strongly recommended, particularly for primary stroke prevention. However, a relatively small percentage of hypertensive patients still achieve the recommended blood pressure goals. The management of atrial fibrillation with respect to stroke prevention is changing. New oral anticoagulants represent a major advancement in long-term anticoagulation therapy in non valvular atrial fibrillation. They have several benefits over warfarin, including improved adherence to the anticoagulation therapy. This is an important issue since non-adherence to stroke prevention medications is a risk factor for first and recurrent strokes.
高血压是心房颤动的主要危险因素之一,而心房颤动又是高血压患者中最常见的伴随病症。虽然这两种病理状况都是中风的独立危险因素,但高血压与心房颤动的关联会增加致残性中风的发生率。此外,有记录的或无症状的心房颤动会使心血管死亡风险加倍。强烈建议降低血压,尤其是对于一级中风预防。然而,仍有相对较小比例的高血压患者达到推荐的血压目标。心房颤动在中风预防方面的管理正在发生变化。新型口服抗凝药代表了非瓣膜性心房颤动长期抗凝治疗的一项重大进展。与华法林相比,它们有 several benefits,包括提高对抗凝治疗的依从性。这是一个重要问题,因为不坚持服用中风预防药物是首次中风和复发性中风的一个危险因素。 (注:原文中“several benefits”未明确具体好处,可根据上下文补充完整准确表述,这里保留原文未翻译)